CoChat

Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development

Open access
Vaklavas, Christos, Blume, Scott W., Grizzle, William E. · 2017 · Frontiers in Oncology
Cited by 73

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Although transcript levels have been traditionally used as a surrogate measure of gene expression, it is increasingly recognized that the latter is extensively and dynamically modulated at the level of translation (messenger RNA to protein). Over the recent years, significant progress has been made in dissecting the complex posttranscriptional mechanisms that regulate gene expression. This advancement in knowledge came hand in hand with the progress made in the methodologies to study translation both at gene-specific as well as global genomic level. The majority of translational control is exerted at the level of initiation; nonetheless, protein synthesis can be modulated at the level of translation elongation, termination, and recycling. Sequence and structural elements and epitranscriptomic modifications of individual transcripts allow for dynamic gene-specific modulation of translation. Cancer cells usurp the regulatory mechanisms that govern translation to carry out translational programs that lead to the phenotypic hallmarks of cancer. Translation is a critical nexus in neoplastic transformation. Multiple oncogenes and signaling pathways that are activated, upregulated, or mutated in cancer converge on translation and their transformative impact "bottlenecks" at the level of translation. Moreover, this translational dysregulation allows cancer cells to adapt to a diverse array of stresses associated with a hostile microenviroment and antitumor therapies. All elements involved in the process of translation, from the transcriptional template, the components of the translational machinery, to the proteins that interact with the transcriptome, have been found to be qualitatively and/or quantitatively perturbed in cancer. This review discusses the regulatory mechanisms that govern translation in normal cells and how translation becomes dysregulated in cancer leading to the phenotypic hallmarks of malignancy. We also discuss how dysregulated mediators or components of translation can be utilized as biomarkers with potential diagnostic, prognostic, or predictive significance. Such biomarkers have the potential advantage of uniform applicability in the face of inherent tumor heterogeneity and deoxyribonucleic acid instability. As translation becomes increasingly recognized as a process gone awry in cancer and agents are developed to target it, the utility and significance of these potential biomarkers is expected to increase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2017.00158

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 184

  1. Sonenberg, 2009, Regulation of translation initiation in eukaryotes: mechanisms and biological targets, Cell, 136, 731, 10.1016/j.cell.2009.01.042 · DOI · Paper page
  2. Boussemart, 2014, eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies, Nature, 513, 105, 10.1038/nature13572 · DOI · Paper page
  3. Cammas, 2016, hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression, Oncotarget, 7, 16793, 10.18632/oncotarget.7589 · DOI
  4. Habibi, 2008, Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes, Breast Cancer Res, 10, R86, 10.1186/bcr2156 · doi:10.1186/bcr2156
  5. Heinonen, 2005, Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma, Cancer Res, 65, 2157, 10.1158/0008-5472.CAN-04-3765 · DOI · Paper page
  6. Heinonen, 2007, Prognostic role of HuR in hereditary breast cancer, Clin Cancer Res, 13, 6959, 10.1158/1078-0432.CCR-07-1432 · DOI · Paper page
  7. Walter, 2009, IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype, Hum Pathol, 40, 1528, 10.1016/j.humpath.2009.05.005 · DOI
  8. Zhou, 2006, Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer, BMC Cancer, 6, 231, 10.1186/1471-2407-6-231 · DOI
  9. Flowers, 2009, Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome, Surgery, 146, 220, 10.1016/j.surg.2009.05.010 · doi:10.1016/j.surg.2009.05.010
  10. Modelska, 2015, The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape, Cell Death Dis, 6, e1603, 10.1038/cddis.2014.542 · DOI · Paper page
  11. McClusky, 2005, A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer, Ann Surg, 242, 584, 10.1097/01.sla.0000184224.55949.90 · DOI
  12. Yin, 2014, Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients, J Am Coll Surg, 218, 663, 10.1016/j.jamcollsurg.2013.12.020 · doi:10.1016/j.jamcollsurg.2013.12.020
  13. Li, 2002, Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome, Ann Surg, 235, 732, 10.1097/00000658-200205000-00016 · DOI
  14. Rojo, 2007, 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis, Clin Cancer Res, 13, 81, 10.1158/1078-0432.CCR-06-1560 · DOI · Paper page
  15. Silvera, 2009, Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer, Nat Cell Biol, 11, 903, 10.1038/ncb1900 · DOI · Paper page
  16. Marcel, 2013, p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer, Cancer Cell, 24, 318, 10.1016/j.ccr.2013.08.013 · DOI · Paper page
  17. Delaunay, 2016, Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer, J Exp Med, 213, 2503, 10.1084/jem.20160397 · DOI · Paper page
  18. Zhao, 2016, High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma, Onco Targets Ther, 9, 2683, 10.2147/OTT.S99939 · DOI
  19. Wang, 2011, Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer, Med Oncol, 28, S577, 10.1007/s12032-010-9734-6 · DOI
  20. Kim, 2011, Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas, Mod Pathol, 24, 1336, 10.1038/modpathol.2011.90 · DOI
  21. Spinola, 2005, Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer, Oncogene, 24, 5502, 10.1038/sj.onc.1208687 · DOI
  22. Zhou, 2013, Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma, Int J Cancer, 132, 1080, 10.1002/ijc.27742 · DOI
  23. Shiraiwa, 2016, Nuclear Y-box-binding protein-1 expression predicts poor clinical outcome in stage III colorectal cancer, Anticancer Res, 36, 3781
  24. Shinkai, 2016, Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models, Int J Cancer, 139, 433, 10.1002/ijc.30075 · DOI
  25. Zhang, 2015, The expression level and prognostic value of Y-box binding protein-1 in rectal cancer, PLoS One, 10, e0119385, 10.1371/journal.pone.0119385 · DOI
  26. Tatarian, 2016, Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer: a post-hoc analysis from the international phase III ESPAC-3 clinical trial, Ann Surg, 10.1097/SLA.0000000000002088 · doi:10.1097/sla.0000000000002088
  27. Mrena, 2005, Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR, Clin Cancer Res, 11, 7362, 10.1158/1078-0432.CCR-05-0764 · DOI · Paper page
  28. Denkert, 2006, Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2, Mod Pathol, 19, 1261, 10.1038/modpathol.3800645 · DOI · Paper page
  29. Okada, 2012, Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma, J Surg Oncol, 105, 780, 10.1002/jso.22108 · DOI
  30. Chen, 2013, Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma, Int J Surg, 11, 85, 10.1016/j.ijsu.2012.11.021 · DOI
  31. Li, 2009, IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis, Ann Surg Oncol, 16, 3499, 10.1245/s10434-009-0648-5 · DOI
  32. Lin, 2013, Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma, Oncol Lett, 6, 740, 10.3892/ol.2013.1458 · DOI
  33. Diab-Assaf, 2015, Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis, Int J Clin Exp Pathol, 8, 404
  34. Chen, 2004, Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome, J Surg Oncol, 86, 22, 10.1002/jso.20037 · DOI
  35. Chao, 2015, eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer, Oncotarget, 6, 24092, 10.18632/oncotarget.4483 · DOI
  36. Fassan, 2010, Programmed cell death 4 protein in esophageal cancer, Oncol Rep, 24, 135, 10.3892/or_00000838 · DOI · Paper page
  37. Fassan, 2010, Programmed cell death 4 (PDCD4) expression during multistep Barrett’s carcinogenesis, J Clin Pathol, 63, 692, 10.1136/jcp.2010.078253 · DOI
  38. Huang, 2016, HNRNPC as a candidate biomarker for chemoresistance in gastric cancer, Tumour Biol, 37, 3527, 10.1007/s13277-015-4144-1 · DOI
  39. Shiota, 2016, Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7, J Natl Cancer Inst, 108, djw005, 10.1093/jnci/djw005 · DOI
  40. Furic, 2010, eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression, Proc Natl Acad Sci U S A, 107, 14134, 10.1073/pnas.1005320107 · DOI · Paper page
  41. Nishio, 2014, Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer, Gynecol Oncol, 132, 703, 10.1016/j.ygyno.2014.01.045 · doi:10.1016/j.ygyno.2014.01.045
  42. Denkert, 2004, Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression, Cancer Res, 64, 189, 10.1158/0008-5472.CAN-03-1987 · DOI · Paper page
  43. Lim, 2007, Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma, Int J Gynecol Pathol, 26, 229, 10.1097/01.pgp.0000236946.82334.07 · DOI
  44. Kobel, 2007, Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma, Oncogene, 26, 7584, 10.1038/sj.onc.1210563 · DOI
  45. Kobel, 2009, IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype, Mod Pathol, 22, 469, 10.1038/modpathol.2008.206 · DOI
  46. Fadare, 2013, Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance, Hum Pathol, 44, 1508, 10.1016/j.humpath.2012.12.003 · DOI
  47. Castellvi, 2009, Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis, Hum Pathol, 40, 1418, 10.1016/j.humpath.2008.12.019 · DOI
  48. Wang, 2008, Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma, Anticancer Res, 28, 2991
  49. Zheng, 2016, YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients, Acta Biochim Biophys Sin (Shanghai), 48, 318, 10.1093/abbs/gmw012 · DOI
  50. Bell, 2015, IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma, J Clin Oncol, 33, 1285, 10.1200/JCO.2014.55.9880 · DOI
  51. Gao, 2009, PDCD4 gene silencing in gliomas is associated with 5’CpG island methylation and unfavourable prognosis, J Cell Mol Med, 13, 4257, 10.1111/j.1582-4934.2008.00497.x · DOI · Paper page
  52. Leprivier, 2013, The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation, Cell, 153, 1064, 10.1016/j.cell.2013.04.055 · DOI · Paper page
  53. Macari, 2016, TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: impact on tumorigenesis, Oncogene, 35, 1785, 10.1038/onc.2015.244 · DOI
  54. Jackson, 2010, The mechanism of eukaryotic translation initiation and principles of its regulation, Nat Rev Mol Cell Biol, 11, 113, 10.1038/nrm2838 · DOI · Paper page
  55. Choe, 2014, eIF4AIII enhances translation of nuclear cap-binding complex-bound mRNAs by promoting disruption of secondary structures in 5’UTR, Proc Natl Acad Sci U S A, 111, E4577, 10.1073/pnas.1409695111 · DOI
  56. Galicia-Vazquez, 2012, A cellular response linking eIF4AI activity to eIF4AII transcription, RNA, 18, 1373, 10.1261/rna.033209.112 · DOI · Paper page
  57. Parsyan, 2011, mRNA helicases: the tacticians of translational control, Nat Rev Mol Cell Biol, 12, 235, 10.1038/nrm3083 · DOI · Paper page
  58. Rogers, 1999, Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A, J Biol Chem, 274, 12236, 10.1074/jbc.274.18.12236 · DOI · Paper page
  59. Rozovsky, 2008, Interactions between eIF4AI and its accessory factors eIF4B and eIF4H, RNA, 14, 2136, 10.1261/rna.1049608 · DOI · Paper page
  60. Feoktistova, 2013, Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity, Proc Natl Acad Sci U S A, 110, 13339, 10.1073/pnas.1303781110 · DOI · Paper page
  61. von der Haar, 2004, The mRNA cap-binding protein eIF4E in post-transcriptional gene expression, Nat Struct Mol Biol, 11, 503, 10.1038/nsmb779 · DOI · Paper page
  62. Lee, 2016, eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation, Nature, 536, 96, 10.1038/nature18954 · DOI · Paper page
  63. Uniacke, 2014, Cancer cells exploit eIF4E2-directed synthesis of hypoxia response proteins to drive tumor progression, Cancer Res, 74, 1379, 10.1158/0008-5472.CAN-13-2278 · DOI · Paper page
  64. Timpano, 2016, Human cells cultured under physiological oxygen utilize two cap-binding proteins to recruit distinct mRNAs for translation, J Biol Chem, 291, 10772, 10.1074/jbc.M116.717363 · DOI
  65. Lee, 2015, eIF3 targets cell-proliferation messenger RNAs for translational activation or repression, Nature, 522, 111, 10.1038/nature14267 · DOI · Paper page
  66. King, 2010, The role of IRES trans-acting factors in regulating translation initiation, Biochem Soc Trans, 38, 1581, 10.1042/BST0381581 · DOI · Paper page
  67. Walters, 2016, Cap-independent translational control of carcinogenesis, Front Oncol, 6, 128, 10.3389/fonc.2016.00128 · DOI
  68. Komar, 2011, Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states, Cell Cycle, 10, 229, 10.4161/cc.10.2.14472 · DOI · Paper page
  69. Chappell, 2004, Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells, Proc Natl Acad Sci U S A, 101, 9590, 10.1073/pnas.0308759101 · DOI
  70. Meng, 2010, The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop, J Cell Biochem, 110, 531, 10.1002/jcb.22569 · DOI
  71. Xue, 2015, RNA regulons in Hox 5’UTRs confer ribosome specificity to gene regulation, Nature, 517, 33, 10.1038/nature14010 · DOI · Paper page
  72. Jack, 2011, rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells, Mol Cell, 44, 660, 10.1016/j.molcel.2011.09.017 · DOI · Paper page
  73. Ruggero, 2003, Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification, Science, 299, 259, 10.1126/science.1079447 · DOI · Paper page
  74. Hertz, 2013, Ribosomal protein S25 dependency reveals a common mechanism for diverse internal ribosome entry sites and ribosome shunting, Mol Cell Biol, 33, 1016, 10.1128/MCB.00879-12 · DOI · Paper page
  75. Spriggs, 2010, Translational regulation of gene expression during conditions of cell stress, Mol Cell, 40, 228, 10.1016/j.molcel.2010.09.028 · DOI · Paper page
  76. Huez, 1998, Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA, Mol Cell Biol, 18, 6178, 10.1128/MCB.18.11.6178 · DOI · Paper page
  77. Sherrill, 2004, BCL-2 translation is mediated via internal ribosome entry during cell stress, J Biol Chem, 279, 29066, 10.1074/jbc.M402727200 · DOI · Paper page
  78. Martineau, 2004, Internal ribosome entry site structural motifs conserved among mammalian fibroblast growth factor 1 alternatively spliced mRNAs, Mol Cell Biol, 24, 7622, 10.1128/MCB.24.17.7622-7635.2004 · DOI
  79. Blau, 2012, Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation, Proc Natl Acad Sci U S A, 109, E2875, 10.1073/pnas.1203659109 · DOI
  80. Dobson, 2013, Dysregulating IRES-dependent translation contributes to over-expression of the aurora A kinase onco-protein, Mol Cancer Res, 11, 887, 10.1158/1541-7786.MCR-12-0707 · DOI
  81. Nanbru, 1997, Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site, J Biol Chem, 272, 32061, 10.1074/jbc.272.51.32061 · DOI · Paper page
  82. Stoneley, 1998, C-Myc 5’ untranslated region contains an internal ribosome entry segment, Oncogene, 16, 423, 10.1038/sj.onc.1201763 · DOI · Paper page
  83. Meng, 2005, The ELAV RNA-stability factor HuR binds the 5’-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation, Nucleic Acids Res, 33, 2962, 10.1093/nar/gki603 · DOI · Paper page
  84. Coldwell, 2000, Initiation of Apaf-1 translation by internal ribosome entry, Oncogene, 19, 899, 10.1038/sj.onc.1203407 · DOI · Paper page
  85. Liu, 2014, Translational reprogramming in cellular stress response, Wiley Interdiscip Rev RNA, 5, 301, 10.1002/wrna.1212 · DOI · Paper page
  86. Li, 2013, The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis, Microbiol Mol Biol Rev, 77, 253, 10.1128/MMBR.00059-12 · DOI
  87. Proud, 2015, Regulation and roles of elongation factor 2 kinase, Biochem Soc Trans, 43, 328, 10.1042/BST20140323 · DOI · Paper page
  88. Alkalaeva, 2006, In vitro reconstitution of eukaryotic translation reveals cooperativity between release factors eRF1 and eRF3, Cell, 125, 1125, 10.1016/j.cell.2006.04.035 · DOI · Paper page
  89. Jackson, 2012, Termination and post-termination events in eukaryotic translation, Adv Protein Chem Struct Biol, 86, 45, 10.1016/B978-0-12-386497-0.00002-5 · DOI · Paper page
  90. Pisarev, 2010, The role of ABCE1 in eukaryotic posttermination ribosomal recycling, Mol Cell, 37, 196, 10.1016/j.molcel.2009.12.034 · DOI · Paper page
  91. Young, 2015, Rli1/ABCE1 recycles terminating ribosomes and controls translation reinitiation in 3’UTRs in vivo, Cell, 162, 872, 10.1016/j.cell.2015.07.041 · DOI · Paper page
  92. Miettinen, 2015, Modified ribosome profiling reveals high abundance of ribosome protected mRNA fragments derived from 3’ untranslated regions, Nucleic Acids Res, 43, 1019, 10.1093/nar/gku1310 · DOI · Paper page
  93. Schleich, 2014, DENR-MCT-1 promotes translation re-initiation downstream of uORFs to control tissue growth, Nature, 512, 208, 10.1038/nature13401 · DOI · Paper page
  94. Jia, 2013, Regulation and dysregulation of 3’UTR-mediated translational control, Curr Opin Genet Dev, 23, 29, 10.1016/j.gde.2012.12.004 · DOI · Paper page
  95. Iwakawa, 2015, The functions of microRNAs: mRNA decay and translational repression, Trends Cell Biol, 25, 651, 10.1016/j.tcb.2015.07.011 · DOI · Paper page
  96. Baltz, 2012, The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts, Mol Cell, 46, 674, 10.1016/j.molcel.2012.05.021 · DOI · Paper page
  97. Glisovic, 2008, RNA-binding proteins and post-transcriptional gene regulation, FEBS Lett, 582, 1977, 10.1016/j.febslet.2008.03.004 · DOI · Paper page
  98. Brummer, 2013, Modeling the binding specificity of the RNA-binding protein GLD-1 suggests a function of coding region-located sites in translational repression, RNA, 19, 1317, 10.1261/rna.037531.112 · DOI
  99. Wurth, 2015, RNA-binding proteins, multifaceted translational regulators in cancer, Biochim Biophys Acta, 1849, 881, 10.1016/j.bbagrm.2014.10.001 · DOI
  100. Grammatikakis, 2017, Posttranslational control of HuR function, Wiley Interdiscip Rev RNA, 8, 10.1002/wrna.1372 · DOI · Paper page
  101. Mukherjee, 2011, Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability, Mol Cell, 43, 327, 10.1016/j.molcel.2011.06.007 · DOI · Paper page
  102. Srikantan, 2011, UneCLIPsing HuR nuclear function, Mol Cell, 43, 319, 10.1016/j.molcel.2011.07.016 · DOI
  103. Wang, 2013, Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis, Int J Mol Sci, 14, 10015, 10.3390/ijms140510015 · DOI · Paper page
  104. Wang, 2000, HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation, EMBO J, 19, 2340, 10.1093/emboj/19.10.2340 · DOI · Paper page
  105. Kim, 2008, Phosphorylated HuR shuttles in cycles, Cell Cycle, 7, 3124, 10.4161/cc.7.20.6884 · DOI · Paper page
  106. Riener, 2009, IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas, Hum Pathol, 40, 1377, 10.1016/j.humpath.2009.01.024 · DOI
  107. Jiang, 2006, Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study, Lancet Oncol, 7, 556, 10.1016/S1470-2045(06)70732-X · DOI · Paper page
  108. Jiang, 2008, Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas, Clin Cancer Res, 14, 5579, 10.1158/1078-0432.CCR-08-0504 · DOI
  109. Sitnikova, 2008, IMP3 predicts aggressive superficial urothelial carcinoma of the bladder, Clin Cancer Res, 14, 1701, 10.1158/1078-0432.CCR-07-2039 · DOI
  110. Bell, 2013, Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?, Cell Mol Life Sci, 70, 2657, 10.1007/s00018-012-1186-z · DOI · Paper page
  111. Bernstein, 1992, Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant, Genes Dev, 6, 642, 10.1101/gad.6.4.642 · DOI · Paper page
  112. Faye, 2015, IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1, Oncogene, 34, 1532, 10.1038/onc.2014.90 · DOI
  113. Lederer, 2014, The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer, Semin Cancer Biol, 29, 3, 10.1016/j.semcancer.2014.07.006 · DOI · Paper page
  114. Galardi, 2016, CPEB1 restrains proliferation of glioblastoma cells through the regulation of p27(Kip1) mRNA translation, Sci Rep, 6, 25219, 10.1038/srep25219 · DOI
  115. Richter, 2007, CPEB: a life in translation, Trends Biochem Sci, 32, 279, 10.1016/j.tibs.2007.04.004 · DOI · Paper page
  116. Grudzien-Nogalska, 2014, CPEB1 promotes differentiation and suppresses EMT in mammary epithelial cells, J Cell Sci, 127, 2326, 10.1242/jcs.144956 · DOI
  117. Nagaoka, 2016, CPEB1 mediates epithelial-to-mesenchyme transition and breast cancer metastasis, Oncogene, 35, 2893, 10.1038/onc.2015.350 · DOI
  118. Ortiz-Zapater, 2011, Key contribution of CPEB4-mediated translational control to cancer progression, Nat Med, 18, 83, 10.1038/nm.2540 · DOI
  119. Perez-Guijarro, 2016, Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers, Nat Commun, 7, 13418, 10.1038/ncomms13418 · DOI
  120. Meyer, 2014, The dynamic epitranscriptome: N6-methyladenosine and gene expression control, Nat Rev Mol Cell Biol, 15, 313, 10.1038/nrm3785 · DOI · Paper page
  121. Gilbert, 2016, Messenger RNA modifications: form, distribution, and function, Science, 352, 1408, 10.1126/science.aad8711 · DOI · Paper page
  122. Iles, 2013, A variant in FTO shows association with melanoma risk not due to BMI, Nat Genet, 45, 428, 10.1038/ng.2571 · DOI · Paper page
  123. Garcia-Closas, 2013, Genome-wide association studies identify four ER negative-specific breast cancer risk loci, Nat Genet, 45, 392, 10.1038/ng.2561 · DOI · Paper page
  124. Molinie, 2016, m(6)A-LAIC-seq reveals the census and complexity of the m(6)A epitranscriptome, Nat Methods, 13, 692, 10.1038/nmeth.3898 · DOI · Paper page
  125. Meyer, 2015, 5’ UTR m(6)A promotes cap-independent translation, Cell, 163, 999, 10.1016/j.cell.2015.10.012 · DOI · Paper page
  126. Zhou, 2015, Dynamic m(6)A mRNA methylation directs translational control of heat shock response, Nature, 526, 591, 10.1038/nature15377 · DOI · Paper page
  127. Jiang, 2017, RNA editing-dependent epitranscriptome diversity in cancer stem cells, Nat Rev Cancer, 17, 381, 10.1038/nrc.2017.23 · DOI
  128. Bahn, 2015, Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways, Nat Commun, 6, 6355, 10.1038/ncomms7355 · DOI · Paper page
  129. Barna, 2008, Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency, Nature, 456, 971, 10.1038/nature07449 · DOI · Paper page
  130. Truitt, 2015, Differential requirements for eIF4E dose in normal development and cancer, Cell, 162, 59, 10.1016/j.cell.2015.05.049 · DOI · Paper page
  131. Shahbazian, 2010, eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways, Cell Cycle, 9, 4106, 10.4161/cc.9.20.13630 · DOI
  132. Lazaris-Karatzas, 1990, Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5’ cap, Nature, 345, 544, 10.1038/345544a0 · DOI · Paper page
  133. Mamane, 2004, eIF4E – from translation to transformation, Oncogene, 23, 3172, 10.1038/sj.onc.1207549 · DOI · Paper page
  134. Yanagiya, 2012, Translational homeostasis via the mRNA cap-binding protein, eIF4E, Mol Cell, 46, 847, 10.1016/j.molcel.2012.04.004 · DOI · Paper page
  135. Koromilas, 1992, mRNAs containing extensive secondary structure in their 5’ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E, EMBO J, 11, 4153, 10.1002/j.1460-2075.1992.tb05508.x · DOI · Paper page
  136. Niedzwiecka, 2002, Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5’ cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins, J Mol Biol, 319, 615, 10.1016/S0022-2836(02)00328-5 · DOI · Paper page
  137. Topisirovic, 2003, The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth, EMBO J, 22, 689, 10.1093/emboj/cdg069 · DOI · Paper page
  138. Ueda, 2004, Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development, Mol Cell Biol, 24, 6539, 10.1128/MCB.24.15.6539-6549.2004 · DOI · Paper page
  139. Scheper, 2002, Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA, J Biol Chem, 277, 3303, 10.1074/jbc.M103607200 · DOI · Paper page
  140. Zuberek, 2003, Phosphorylation of eIF4E attenuates its interaction with mRNA 5’ cap analogs by electrostatic repulsion: intein-mediated protein ligation strategy to obtain phosphorylated protein, RNA, 9, 52, 10.1261/rna.2133403 · DOI · Paper page
  141. Pettersson, 2015, Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis, Cancer Res, 75, 1102, 10.1158/0008-5472.CAN-14-1996 · DOI
  142. Robichaud, 2015, Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3, Oncogene, 34, 2032, 10.1038/onc.2014.146 · DOI · Paper page
  143. Gandin, 2016, mTORC1 and CK2 coordinate ternary and eIF4F complex assembly, Nat Commun, 7, 11127, 10.1038/ncomms11127 · DOI · Paper page
  144. Roux, 2012, Regulation of mRNA translation by signaling pathways, Cold Spring Harb Perspect Biol, 4, a012252, 10.1101/cshperspect.a012252 · DOI · Paper page
  145. Alain, 2012, eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies, Cancer Res, 72, 6468, 10.1158/0008-5472.CAN-12-2395 · DOI · Paper page
  146. Tsukumo, 2016, Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3, Nat Commun, 7, 11776, 10.1038/ncomms11776 · DOI
  147. Raught, 2004, Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases, EMBO J, 23, 1761, 10.1038/sj.emboj.7600193 · DOI · Paper page
  148. Shahbazian, 2006, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity, EMBO J, 25, 2781, 10.1038/sj.emboj.7601166 · DOI · Paper page
  149. Shahbazian, 2010, Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B, Mol Cell Biol, 30, 1478, 10.1128/MCB.01218-09 · DOI · Paper page
  150. Mayer, 2004, mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability, Genes Dev, 18, 423, 10.1101/gad.285504 · DOI · Paper page
  151. Michels, 2010, mTORC1 directly phosphorylates and regulates human MAF1, Mol Cell Biol, 30, 3749, 10.1128/MCB.00319-10 · DOI · Paper page
  152. Wei, 2009, Mechanisms of regulation of RNA polymerase III-dependent transcription by TORC1, EMBO J, 28, 2220, 10.1038/emboj.2009.179 · DOI · Paper page
  153. Fernandez, 2003, Genomic targets of the human c-Myc protein, Genes Dev, 17, 1115, 10.1101/gad.1067003 · DOI · Paper page
  154. Lin, 2009, c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy, Cancer Res, 69, 7491, 10.1158/0008-5472.CAN-09-0813 · DOI
  155. Khanna-Gupta, 2012, Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein alpha activity: implications in myelodysplastic syndrome and acute myeloid leukemia, J Biol Chem, 287, 32728, 10.1074/jbc.M112.373274 · DOI
  156. Hariri, 2013, The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-kappaB and is aberrantly regulated in acute myeloid leukemia, Leukemia, 27, 2047, 10.1038/leu.2013.73 · DOI
  157. Yi, 2013, Hypoxia-inducible factor-1alpha (HIF-1alpha) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions, J Biol Chem, 288, 18732, 10.1074/jbc.M113.471466 · DOI · Paper page
  158. Topisirovic, 2009, Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer, Mol Cell Biol, 29, 1152, 10.1128/MCB.01532-08 · DOI · Paper page
  159. Koromilas, 2015, Roles of the translation initiation factor eIF2alpha serine 51 phosphorylation in cancer formation and treatment, Biochim Biophys Acta, 1849, 871, 10.1016/j.bbagrm.2014.12.007 · DOI
  160. Holcik, 2015, Could the eIF2alpha-independent translation be the Achilles heel of cancer?, Front Oncol, 5, 264, 10.3389/fonc.2015.00264 · DOI · Paper page
  161. Somers, 2015, A common polymorphism in the 5’ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy, Genes Dev, 29, 1891, 10.1101/gad.261867.115 · DOI
  162. Richter, 2015, Pausing on polyribosomes: make way for elongation in translational control, Cell, 163, 292, 10.1016/j.cell.2015.09.041 · DOI · Paper page
  163. Reid, 2015, Diversity and selectivity in mRNA translation on the endoplasmic reticulum, Nat Rev Mol Cell Biol, 16, 221, 10.1038/nrm3958 · DOI · Paper page
  164. Jagannathan, 2014, Multifunctional roles for the protein translocation machinery in RNA anchoring to the endoplasmic reticulum, J Biol Chem, 289, 25907, 10.1074/jbc.M114.580688 · DOI
  165. Reid, 2012, Primary role for endoplasmic reticulum-bound ribosomes in cellular translation identified by ribosome profiling, J Biol Chem, 287, 5518, 10.1074/jbc.M111.312280 · DOI · Paper page
  166. Chaudhury, 2010, TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI, Nat Cell Biol, 12, 286, 10.1038/ncb2029 · DOI · Paper page
  167. Hussey, 2011, Identification of an mRNP complex regulating tumorigenesis at the translational elongation step, Mol Cell, 41, 419, 10.1016/j.molcel.2011.02.003 · DOI · Paper page
  168. Ryazanov, 1988, Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation, Nature, 334, 170, 10.1038/334170a0 · DOI · Paper page
  169. Faller, 2015, mTORC1-mediated translational elongation limits intestinal tumour initiation and growth, Nature, 517, 497, 10.1038/nature13896 · DOI · Paper page
  170. Liu, 2014, Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K, EMBO Mol Med, 6, 1542, 10.15252/emmm.201404402 · DOI · Paper page
  171. Xue, 2012, Specialized ribosomes: a new frontier in gene regulation and organismal biology, Nat Rev Mol Cell Biol, 13, 355, 10.1038/nrm3359 · DOI · Paper page
  172. Novoa, 2012, Speeding with control: codon usage, tRNAs, and ribosomes, Trends Genet, 28, 574, 10.1016/j.tig.2012.07.006 · DOI · Paper page
  173. Pavon-Eternod, 2013, Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells, RNA, 19, 461, 10.1261/rna.037507.112 · DOI · Paper page
  174. Felton-Edkins, 2003, Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc, Cell Cycle, 2, 181, 10.4161/cc.2.3.375 · DOI · Paper page
  175. Felton-Edkins, 2003, The mitogen-activated protein (MAP) kinase ERK induces tRNA synthesis by phosphorylating TFIIIB, EMBO J, 22, 2422, 10.1093/emboj/cdg240 · DOI
  176. Gingold, 2014, A dual program for translation regulation in cellular proliferation and differentiation, Cell, 158, 1281, 10.1016/j.cell.2014.08.011 · DOI · Paper page
  177. Pavon-Eternod, 2009, tRNA over-expression in breast cancer and functional consequences, Nucleic Acids Res, 37, 7268, 10.1093/nar/gkp787 · DOI · Paper page
  178. Grewal, 2015, Why should cancer biologists care about tRNAs? tRNA synthesis, mRNA translation and the control of growth, Biochim Biophys Acta, 1849, 898, 10.1016/j.bbagrm.2014.12.005 · DOI
  179. Gu, 2014, tRNA modifications regulate translation during cellular stress, FEBS Lett, 588, 4287, 10.1016/j.febslet.2014.09.038 · DOI · Paper page
  180. Park, 2008, Aminoacyl tRNA synthetases and their connections to disease, Proc Natl Acad Sci U S A, 105, 11043, 10.1073/pnas.0802862105 · DOI · Paper page
  181. Jia, 2008, WHEP domains direct noncanonical function of glutamyl-prolyl tRNA synthetase in translational control of gene expression, Mol Cell, 29, 679, 10.1016/j.molcel.2008.01.010 · DOI · Paper page
  182. McCune, 1979, Neoplastic transformation-linked alterations in arginyl-tRNA synthetase activity, Biochim Biophys Acta, 561, 410, 10.1016/0005-2787(79)90149-7 · doi:10.1016/0005-2787(79)90149-7
  183. Thomas, 1982, Comparison of complexes containing lysyl-tRNA synthetase from normal and virus-transformed cells, Can J Biochem, 60, 804, 10.1139/o82-100 · doi:10.1139/o82-100
  184. Kim, 2011, Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping, Nat Rev Cancer, 11, 708, 10.1038/nrc3124 · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Vaklavas, C., Blume, S. W., & Grizzle, W. E.
Venue
Frontiers in Oncology
Published
2017-07-26
Volume
7
Pages
158-158
ISSN
2234-943X (ISSN-L)
OpenAlex
W2738737902
Cited by
73
References
23
FWCI
2.72
Type
journal article
Language
en
Open access
gold
Funders
Susan G. Komen for the Cure (CCR15331062)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. https://app.cochat.ai/papers/10.3389/fonc.2017.00158
The paper
Vaklavas, C., Blume, S. W., & Grizzle, W. E. (2017). Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. Frontiers in Oncology. https://doi.org/10.3389/fonc.2017.00158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.